This page shows the latest clopidogrel news and features for those working in and with pharma, biotech and healthcare.
The CHMP also recommended marketing authorisations for two generic medicines – Mylan’s Clopidogrel/Acetylsalicylic acid Mylan (clopidogrel/acetylsalicylic acid) for the secondary prevention of atherothrombotic events and Accord’s
Last year, the GLOBAL LEADERS study last year also showed that discontinuing aspirin after a month and starting monotherapy with ticagrelor was no better than aspirin plus Brilinta or clopidogrel in
Brilinta (ticagrelor) was unable to show any improvement over an older generic antiplatelet drug - clopidogrel - in the large-scale EUCLID trial, which enrolled almost 14, 000 people with symptomatic PAD. ... Billed as the largest cardiovascular outcomes
superiority to Sanofi's Plavix (clopidogrel), a former blockbuster now subject to generic competition.
Brilinta was previously approved as 90mg tablet given twice-daily after being shown to be superior to clopidogrel in the PLATO trial, and the new indication gives a green light to ... However, it has been suggested the PEGASUS data could also lead to
into a market formerly dominated by Sanofi's Plavix (clopidogrel) which lost patent protection in 2012. ... The overall occurrence of serious bleeding was low but more common with Kengreal than with clopidogrel, with one in every 170 Kengreal-treated
More from news
Approximately 1 fully matching, plus 77 partially matching documents found.
Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily aspirin and/or clopidogrel to reduce thrombotic cardiovascular events.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...